Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations
Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with…
FDA OKs New Option for Advanced ROS1-Positive Lung Cancer
The FDA approved repotrectinib (Augtyro) -- an oral tyrosine kinase inhibitor (TKI)…
Pembrolizumab Wins FDA Approval in Operable Lung Cancer
The FDA approved pembrolizumab (Keytruda) on Monday in combination with platinum-based chemotherapy…
New Lung Cancer Cases Are Higher in Younger Women vs Men
Updated population-based data showed that while lung cancer incidence rates are continuing…
Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC
The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic…
Sotorasib’s Confirmatory Data in NSCLC Unreliable, Says FDA Panel
An FDA advisory committee on Thursday said the confirmatory trial data for…
Drugmaker Plans to Pull Lung Cancer Therapy From the Market
Mobocertinib (Exkivity) will be withdrawn from the U.S. market after a failed…
FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC
Ahead of a meeting of the Oncologic Drugs Advisory Committee on Thursday,…
Anti-TIGIT Plus Immunotherapy ‘Promising’ in NSCLC, Esophageal Cancer
Combination treatment with an investigational anti-TIGIT drug plus a PD-L1 inhibitor was…
